| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_67560c482293eda7d3261c982a09360f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_936c424cb4b043160d5ae6fa92be6585
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9e2865addfaa2b982970a2e8f9966a75 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439 |
| filingDate |
2006-02-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_337d7aa2096bf8db6b0325508611a8ed
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4edff8e1d7dbfa4ea4b95f4dd727f6c1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d65a95430f837921464088732f54ba1d |
| publicationDate |
2006-06-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2006142346-A1 |
| titleOfInvention |
S-lansoprazole compositions and methods |
| abstract |
Methods and compositions are disclosed utilizing optically pure (−) lansoprazole for the treatment of ulcers in humans while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of lansoprazole. The optically pure (−) isomer is also useful for the treatment of gastroesophageal reflux. (−) Lansoprazole is an inhibitor of H + release and is therefore useful in the treatment of other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome. |
| priorityDate |
1999-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |